2026-01-24 - Analysis Report
**Company Overview**
Invesco is an American investment management company that offers a range of asset management and investment products.

**Return Rate Comparison**
The return rate of IVZ is 81.97% compared to 126.41% for S&P 500 (VOO). The divergence is -44.40, with a relative divergence of 55.10%.

**Alpha and Beta Analysis**
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | -30.0% | 36.6% | -43.0% | 1.4 | 7.5B |
| 2017-2019 | -21.0% | 36.6% | -46.0% | 1.2 | 8.0B |
| 2018-2020 | -23.0% | 57.7% | -47.0% | 1.5 | 7.8B |
| 2019-2021 | 58.0% | 57.7% | -8.0% | 1.6 | 10.3B |
| 2020-2022 | 26.0% | 57.7% | 19.0% | 1.6 | 8.0B |
| 2021-2023 | -7.0% | 41.9% | -27.0% | 1.5 | 8.0B |
| 2022-2024 | -13.0% | 35.9% | -42.0% | 1.4 | 7.8B |
| 2023-2025 | 65.0% | 34.8% | -10.0% | 1.5 | 11.7B |

**Recent Stock Price Fluctuations**
- Close: $28.40
- Last-market: $28.40 (price), $29.24 (previousClose), -2.87 (change)
- 5-day SMA: $28.83
- 20-day SMA: $28.02
- 60-day SMA: $25.78

**Risk and Trend Analysis**
- Market Risk Indicator (MRI): 0.70
- RSI: 58.75
- PPO: -0.23
- Hybrid Signal: Buy
- Risk Level: Medium (MRI 0.70)
- Recent (20 days) relative divergence change: -4.50 (-): worsening
- 7-day Rank change: 112 (+): rank up
- 7-day Dynamic Expected Return change: 49.60 (+): improving
- Expected Return (%): -61.70%

**Recent News & Significant Events**
- [2026-01-23] Does RBC’s IVZ Upgrade and QQQ Reclassification Alter Invesco’s Active–Passive Growth Balance? - simplywall.st
- [2026-01-23] Invesco: Asset Manager Hits Ceiling Of Fair Value - Seeking Alpha
- [2026-01-23] How Invesco Ltd (IVZ) Affects Rotational Strategy Timing - Stock Traders Daily
- [2026-01-21] Invesco (IVZ) Stock Trades Up, Here Is Why - The Globe and Mail
- [2026-01-22] Assessing Invesco (IVZ) Valuation After RBC Capital’s Outperform Upgrade And QQQ ETF Earnings Tailwind - Yahoo Finance
- [2026-01-21] IVZ Stock Upgraded to "Outperform" with Raised Price Target by R - GuruFocus

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.33 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 30.30 / 35.00 / 24.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-11-04 | 0.67 | $1.64B |
| 2025-08-01 | -0.03 | $1.52B |
| 2025-04-28 | 0.38 | $1.53B |
| 2024-10-29 | 0.12 | $1.52B |
| 2025-11-04 | 0.12 | $1.52B |

**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $1.64B | 34.17% |
| 2025-06-30 | $1.52B | 33.28% |
| 2025-03-31 | $1.53B | 36.33% |
| 2024-12-31 | $1.59B | 37.83% |
| 2024-09-30 | $1.52B | 25.76% |

**Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $14.01B | 2.47% |
| 2025-06-30 | $13.87B | 1.47% |
| 2025-03-31 | $14.70B | 1.57% |
| 2024-12-31 | $14.56B | 1.84% |
| 2024-09-30 | $14.75B | 0.77% |

**Comprehensive Analysis**
Based on the analysis of IVZ's return rate, alpha and beta, risk and trend analysis, news, analyst opinions, earnings, and financial data, the following conclusions can be drawn:

* IVZ's return rate has been lagging behind the S&P 500, with a divergence of -44.40 and a relative divergence of 55.10%.
* The company's alpha and beta values have been volatile over the years, with some years showing positive and others negative.
* The risk and trend analysis show that IVZ is currently in a medium-risk category, with a market risk indicator of 0.70 and a relative divergence of -4.50.
* The recent news and significant events suggest that the company faces challenges in maintaining its active-passive growth balance and in achieving a fair valuation.
* The analyst opinions are mixed, with a mean opinion score of 2.33 (~Buy) and a target price range of 24.00 to 35.00.
* The recent earnings analysis shows that the company's EPS has fluctuated over the years, with a current EPS of 0.67.
* The financial data show that the company's revenue and profit margin have been volatile over the years, with some quarters showing higher and others lower.

Overall, the comprehensive analysis suggests that IVZ is facing challenges in maintaining its return rate, managing its risk, and achieving a fair valuation. The company's earnings and financial data show signs of volatility, and the analyst opinions are mixed. Therefore, investors should exercise caution when considering IVZ as an investment opportunity.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.